Keros Therapeutics (NASDAQ:KROS) Rating Increased to Strong-Buy at Wedbush

Wedbush upgraded shares of Keros Therapeutics (NASDAQ:KROS) to a strong-buy rating in a research report sent to investors on Monday, Zacks.com reports. Wedbush also issued estimates for Keros Therapeutics’ Q4 2025 earnings at ($1.27) EPS.

KROS has been the subject of a number of other reports. Scotiabank began coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price objective for the company. Cantor Fitzgerald began coverage on shares of Keros Therapeutics in a research note on Thursday, October 24th. They issued an “overweight” rating on the stock. Bank of America cut their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research report on Thursday, September 12th. Jefferies Financial Group assumed coverage on Keros Therapeutics in a research report on Tuesday. They issued a “buy” rating on the stock. Finally, Guggenheim assumed coverage on Keros Therapeutics in a report on Monday, September 23rd. They set a “buy” rating and a $96.00 price target for the company. Eleven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $89.11.

Keros Therapeutics Stock Up 4.4 %

KROS stock opened at $62.58 on Monday. Keros Therapeutics has a twelve month low of $27.31 and a twelve month high of $73.00. The company has a market cap of $2.35 billion, a price-to-earnings ratio of -12.20 and a beta of 1.23. The business has a 50 day moving average price of $56.87 and a two-hundred day moving average price of $51.89.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). The firm had revenue of $0.04 million during the quarter. Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. During the same period in the prior year, the company posted ($1.27) EPS. On average, equities research analysts anticipate that Keros Therapeutics will post -4.9 EPS for the current fiscal year.

Insider Activity at Keros Therapeutics

In other Keros Therapeutics news, Director Carl L. Gordon sold 250,000 shares of the company’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the sale, the director now directly owns 119,522 shares in the company, valued at $5,260,163.22. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 22.90% of the stock is currently owned by insiders.

Institutional Trading of Keros Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of KROS. Mirae Asset Global Investments Co. Ltd. increased its holdings in Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after purchasing an additional 280 shares during the period. Values First Advisors Inc. bought a new stake in shares of Keros Therapeutics during the 3rd quarter valued at about $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Keros Therapeutics during the second quarter worth approximately $128,000. Ameritas Investment Partners Inc. increased its holdings in Keros Therapeutics by 14.5% in the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after purchasing an additional 324 shares in the last quarter. Finally, Victory Capital Management Inc. acquired a new position in Keros Therapeutics in the third quarter valued at approximately $216,000. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.